Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells

Clinical trial NCT04991532 · UNKNOWN

Trial details

NCT number: NCT04991532
Sponsor: Nanfang Hospital, Southern Medical University
Status: UNKNOWN
Study type: OBSERVATIONAL

Chronic Myeloid Leukemia

Start date: 2021-06-20
Primary completion: 2022-10-01
Enrollment: 324

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.